TuHURA Appoints SVP to Boost Phase 3 IFx-2.0, Phase 1b/2 TBS-2025 and ADCs
TuHURA Biosciences named Amanda Garofalo as Senior VP of Clinical Operations to oversee its Phase 3 IFx-2.0 trial, Phase 1b/2 TBS-2025 program and early-stage ADCs research. She brings over 20 years’ experience in Phase I-IV development, including leading enrollment for a $305 million Series F and managing 200+ oncology trials.
1. Leadership Appointment
On April 7, 2026, TuHURA Biosciences appointed Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations. She will partner with Dr. James Bianco to streamline day-to-day oversight across all ongoing clinical studies.
2. Clinical Operations Expertise
Garofalo brings over 20 years of drug and biologic development experience, most recently enabling enrollment for a $305 million Series F at Parabilis Medicines and managing a portfolio of 200+ Phase I-IV oncology trials at EMD Serono.
3. Pipeline Oversight
In her new role she will lead the Phase 3 accelerated approval trial for IFx-2.0, guide the Phase 1b/2 study of TBS-2025 in mutNPM1 r/r AML, and direct pre-clinical planning for TuHURA’s early-stage antibody-drug conjugates program.